DUBLIN--(BUSINESS WIRE)--The "Male Infertility - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Male Infertility - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
This pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies Featured
- Cadila Healthcare Ltd.
- Health Ever Bio-Tech Co. Ltd.
Key Topics Covered
1. Introduction
2. Report Coverage
3. Male Infertility - Overview
4. Male Infertility - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Male Infertility - Therapeutics Assessment
11. Male Infertility - Companies Involved in Therapeutics Development
12. Male Infertility - Drug Profiles
13. Male Infertility - Dormant Projects
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rlctsj/male_infertility?w=4
